China Pharmaceuticals & Clinical Research Reservations open Page created Nov 16, 2026

List of NMPA-Registered Drug Clinical Trial Institutions in China

Hospitals and other institutions in mainland China that have filed as drug clinical trial institutions under the NMPA record-filing system, with their city, filed drug trial specialties and Phase I capability, for sponsors, CROs and SMOs shortlisting sites before feasibility outreach.

Fields we plan to include

Institution name (English and Chinese)
Province / municipality
City
Filing number
Filed drug trial specialties
Number of filed specialties
Phase I unit / phase scope
Medical device trial filing
Hospital grade
Institution website
Clinical trial office general contact

Data Preview

* Free sample rows, unverified and may contain errors. This list isn't for sale yet.
InstitutionCityFiled drug specialtiesPhase scope (as published)
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & TechnologySourceWuhan54Phase I, II, III and IV
Beijing Tsinghua Changgung HospitalSourceBeijingOver 31Phase I-IV
Beijing Ditan HospitalSourceBeijing13Phase I Clinical Trial Unit
Obstetrics and Gynecology Hospital affiliated to Zhejiang University School of MedicineSourceHangzhou4Phase II, III and IV
Beijing Huaxin HospitalSourceBeijing3Phase I–IV

Estimated ~1,800 entries. If people reserve it, we'll try to compile it (we can't compile every list).

* No charge now. Purchase is optional.

How China's drug clinical trial institution filing works

Since 1 December 2019, a hospital in mainland China no longer needs a government accreditation certificate to run registration trials for drugs. The revised Drug Administration Law replaced accreditation with record filing: an institution that meets the conditions set by the NMPA and the National Health Commission enters its information on the national drug clinical trial institution record-filing platform operated by the Center for Food and Drug Inspection (CFDI), and the platform issues a filing number. Accreditation certificates issued before 2019 are therefore not the right test of whether a site may run a trial today; the filing record is.

What a filing record contains

Filing is not one yes/no status. Each institution files a set of specialties (for example cardiology, oncology, hepatology, pediatric respiration), and a trial may only run in a filed specialty. Institutions add specialties over time, so two hospitals of similar size can differ widely: in the sample on this page, one Wuhan teaching hospital has filed 54 drug specialties, while a specialist women's hospital in Hangzhou lists four and a newer Beijing hospital lists three.

  • Filing number and date - issued by the platform when the filing is completed; the filing date shows how long a site has operated under the current system.
  • Filed specialties - the scope that matters for site selection. A site with an excellent oncology department but no filed oncology specialty cannot host your oncology study until it files one.
  • Phase I clinical trial ward - first-in-human, healthy-volunteer and bioequivalence studies must run in a filed Phase I specialty with its own beds, so Phase I capability is a separate filter, not something implied by hospital size.
  • Medical device filing - a separate record on the same platform; a hospital's device specialties often differ from its drug specialties.

Scale and geography

The platform had about 1,000 filed institutions by May 2021, and a 2025 analysis drawing on the same platform counted 1,803 as of 9 September 2025. Activity is concentrated: NMPA's annual reports on clinical trials note that leading and participating sites are still mainly in Beijing, Shanghai, Jiangsu and Guangdong. For feasibility this means a shortlist built only from well-known tertiary hospitals in tier-1 cities will compete with every other sponsor for the same investigators, while filed sites in provincial capitals may offer faster start-up for common indications.

Using filing data in site feasibility

  1. Start from the indication, not the hospital. Map the indication to the filed specialty names used on the platform, then list every institution that holds that specialty in your target provinces.
  2. Separate Phase I from Phase II-IV. Only a minority of filed institutions have a Phase I ward; a 2025 study of one western province found just 22 Phase I units among its filed institutions.
  3. Check filing dates. Under the 2023 NMPA inspection measures, a newly filed institution or specialty is inspected after filing, with the first inspection focused on whether the filing conditions are really met. Recent filings carry more start-up uncertainty than long-established ones.
  4. Confirm ethics review arrangements. Under the 2025 30-day IND review pathway, applicants must assess the ethics review capability and compliance record of the leading institution and its principal investigator, so the lead site's ethics committee is part of feasibility, not an afterthought.
The official platform is in Chinese and shows one institution record at a time. An English, attribute-joined view (province, filing number, specialties, Phase I capability) is what most international feasibility teams end up building by hand.

Frequently Asked Questions

Q.What replaced GCP accreditation for drug clinical trial sites in China?

Since 1 December 2019, drug clinical trial institutions in China are subject to record filing instead of accreditation. An institution that meets the NMPA and National Health Commission conditions files on the national record-filing platform run by the CFDI and receives a filing number; trials may only run in the specialties it has filed.

Q.Can any filed hospital run a Phase I or bioequivalence study?

No. Healthy-volunteer, first-in-human and bioequivalence studies must be conducted in a filed Phase I clinical trial specialty with dedicated ward beds. Many filed hospitals only hold Phase II-IV specialties, so Phase I capability has to be checked separately for each site.

Q.Why does the filing date of a site matter for start-up?

NMPA inspects newly filed institutions and newly added specialties after filing, and the first inspection focuses on whether the filing conditions are actually met. A recently filed site or specialty may therefore face an inspection during your study, which is worth factoring into start-up timelines.

Q.Are drug and medical device trial filings the same?

No. Drug and medical device clinical trial institutions are filed separately on the same platform, and a hospital's device specialties often differ from its drug specialties. A site filed for device trials in a therapeutic area is not automatically filed for drug trials in it.

Q.Can I buy the list now?

Not yet. Sample rows are free. We try to compile lists that people reserve (we can't compile every list). If we do, we'll email everyone who reserved it a purchase link (buying is optional). If we don't, nothing happens and you're never charged.

Q.What does it cost?

Sample rows are free. A list is $49, paid only if we compile it and you decide to buy. There is no free trial or subscription.